Skip to main content
GoodMoatv1.1
Sign in
VRTX logo

VRTX

CompareEarnings: May 31, 2026

Vertex Pharmaceuticals Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For.

Did you know?

Profit margin of 32.9% — that's well above average.

Current Price

$446.78

+0.64%

GoodMoat Value

$284.70

36.3% overvalued
Profile
Valuation (TTM)
Market Cap$113.36B
P/E28.67
EV$110.43B
P/B6.07
Shares Out253.72M
P/Sales9.45
Revenue$12.00B
EV/EBITDA22.32

Vertex Pharmaceuticals Inc (VRTX) Company Profile

GoodMoat Analysis

Based on data as of March 26, 2026

Vertex is a highly profitable biotech leader with a near-monopoly on treatments for cystic fibrosis, creating a powerful moat. However, its valuation appears elevated, and its long-term growth depends on successfully expanding beyond its core franchise.

Read full analysis
Vertex Pharmaceuticals develops and sells therapies for serious diseases, primarily cystic fibrosis (CF). Its customers are patients and healthcare systems. Vertex has built a formidable moat through regulatory barriers and technology leadership. It holds patents and regulatory exclusivity for the only approved drugs that treat the underlying cause of CF, not just the symptoms. This creates a near-monopoly, satisfying Moat criteria #5 (Regulatory Barriers) and #9 (Technology Leadership). Its financials are strong, with a robust profit margin of 32.9% and an ROE of 21.2%, which exceeds the 15-20% high-quality threshold. However, key risks from the framework are present. There is high customer concentration risk on its CF franchise (a High Confidence Red Flag), and future growth depends on pipeline execution to move beyond CF, which carries inherent execution risk. A value investor might be interested in its durable cash flows but cautious given its P/E of 29.2x and a GoodMoat Target price of $284.70, which suggests the current price of $454.97 may not offer a margin of safety. The modest revenue growth of 9.5% YoY also raises questions about justifying the premium valuation.

VRTX Company Information

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions.

The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas.

Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.

Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London.

Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East.

Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For.

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

Massachusetts, USA

VRTX Key Officers

Key officers data coming soon

VRTX Company Profile

Vertex Pharmaceuticals Inc (VRTX) is a Healthcare company in the Biotechnology industry. It trades on NASDAQ. The company is based in Massachusetts, USA.

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For.

Market cap is $113.36B. There are 253.7M shares outstanding.

See the full Vertex Pharmaceuticals Inc profile on GoodMoat. It covers key officers, financial metrics, and sector details. You can also use GoodMoat's DCF calculator, fair value models, and quality score to help decide if VRTX is a good investment.